Personally i just don't know how to value MAP at the moment. Making some assumptions about revenue growth in the testing/analysis side of the business is easy enough but adding the clinical trial side is problematic. Trials add a lot of expense and will be a drag on the bottom line, but on the flip side provide potential upside IF they are successful.
I think my conclusion is there are other companies with similar market caps that have assets in trials I believe have more upside; and companies with similar revenue and growth potential that might better reflect that in the short to medium term.
Welcome alternative views on this.
will keep watching.
General discussion, page-13
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $78.37M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $22.11K | 122.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12556 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 64647 | 3 |
View Market Depth
| Last trade - 15.50pm 02/10/2024 (20 minute delay) ? |
| MAP (ASX) Chart |